For the quarter ending 2025-12-31, RGBPP made $59,065 in revenue. -$967,853 in net income. Net profit margin of -1638.62%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Net revenue | 59,065 | 59,165.333 | 59,065 | |
| Research and development | 210,000 | 3,908.333 | 0 | |
| General and administrative | 231,925 | 14,805.333 | 30,697 | |
| Consulting and professional fees | 153,764 | 117,213 | 46,624 | |
| Rent | 15,000 | 22,500 | 22,500 | |
| Total operating expenses | 610,689 | 158,426.667 | 99,821 | |
| Loss from operations | -551,624 | -99,261.333 | -40,756 | |
| Interest expense | 26,553 | 44,549.333 | 24,638 | |
| Interest expense attributable to amortization of discount | 8,850 | 13,169.667 | 12,639 | |
| Derivative income (expense) | -380,826 | -195,423 | -89,259 | |
| Penalties | 0 | 12,500 | - | |
| Financing fees | 0 | - | - | |
| Total other income (expense), net | -416,229 | -269,808.667 | -126,536 | |
| Net loss before income taxes | -967,853 | -369,070 | -167,292 | |
| Income tax provision | 0 | 0 | 0 | |
| Net loss | -967,853 | -369,070 | -167,292 | |
| Net loss per common share, basic | -0.01 | -0.013 | -0.01 | |
| Net loss per common share, diluted | -0.01 | -0.013 | -0.01 | |
| Number of weighted average shares - basic | 99,609,650 | -76,845.333 | 23,752,506 | |
| Number of weighted average shares - diluted | 99,609,650 | -76,845.333 | 23,752,506 | |
Regen BioPharma Inc (RGBPP)
Regen BioPharma Inc (RGBPP)